痛风治疗用药--非布司他

Febuxostat (febuxostat, feburic) is a highly effective xanthine oxidase inhibitor. Through the molybdopterin center of xanthine oxidase, it keeps the oxidized or reduced molybdenum factor in an isolated state, thereby reducing the binding of xanthine oxidase to its substrate and reducing the production of uric acid. In this way, the concentration of uric acid in the blood can be reduced, so as to treat hyperuricemia or gout.

A phase III clinical trial compared the efficacy of febuxostat (80 and 120 mg/d) and allopurinol (300 mg/d) in parallel. A 1-year study of 760 patients showed that compared with the allopurinol group, more patients in the allopurinol group achieved the main trial efficacy indicator - the sUA concentration measured in the last 3 months was less than 60 mg/L (all subjects were gout patients, and the sUA concentration before the trial were all above 80 mg/L); after 52 weeks of treatment, Febubu Sustat (febuxostat, feburic) failed to significantly reduce the area of tophi (tophi is an aggregate of urate crystals unique to gout), but the effect was more obvious in the high-dose group in the early stages of the trial; in each treatment group, patients with sUA concentrations reaching the target (<60 mg/L) were less likely to have gout attacks again, and their tophi area was more significantly reduced.

Febuxostat has no significant activity on other purine and pyrimidine metabolism enzymes, will not affect enzymes other than xanthine oxidase, will not produce toxic side effects similar to allopurinol, and is highly safe. However, the drug is toxic. Febuxostat can also cause skin allergic reactions, which were first reported by American scholars in 2012. The main symptoms are skin itching, rash, etc. If this occurs, antihistamines and glucocorticoids need to be treated, and attention should be paid during use. Abnormal liver function is also one of the common adverse reactions of febuxostat, manifesting as fatigue, loss of appetite, jaundice, diarrhea, etc.